

Article

Not peer-reviewed version

Lobocalines A–I: Antibacterial Diterpenes and Steroids From the South China Sea Soft Coral *Lobophytum catalai*

Sheng-Hui Zhu , Yuan-Min Chang , [Ming-Zhi Su](#) , Li-Gong Yao , Song-Wei Li , [Hong Wang](#) , [Yue-Wei GUO](#) *

Posted Date: 29 December 2023

doi: 10.20944/preprints202312.2259.v1

Keywords: Lobophytum catalai; antibacterial activity; soft coral; structural elucidation



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

Lobocalines A–I: Antibacterial Diterpenes and Steroids from the South China Sea soft coral *Lobophytum catalai*

Sheng-Hui Zhu ^{2,3}, Yuan-Min Chang ², Ming-Zhi Su ², Li-Gong Yao ², Song-Wei Li ^{1,*} and Hong Wang ^{3,*} and Yue-Wei Guo ^{1,2,3,*}

¹ School of Medicine, Shanghai University, Shanghai 200444, China

² Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China; zhushenghui0115@163.com (S.-H. Z.); 13153672940@163.com (Y.-M.C.); smz0310@163.com (M.-Z.S.); yaoligong@sim.ac.cn (L.-G.Y.)

³ Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals and College of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China

* Correspondence: simmswli@163.com (S.-W. L.); hongw@zjut.edu.cn (H.W.); ywguo@sim.ac.cn (Y.-W.G.)

Abstract: Five new cembrane-type diterpenes, lobocalines A–E (1–5), and four new steroids, lobocalines F–I (9–12), along with six known related compounds (6–8 and 13–15) were isolated from the Yalong Bay soft coral *Lobophytum catalai*. The structures of the new compounds were elucidated by extensive spectroscopic analysis, NMR calculation with DP4+ analysis, time-dependent density functional theory-electronic circular dichroism (TDDFT-ECD) calculations, X-ray diffraction analyses, and the comparison with the reported spectroscopic data of known compounds. Further, with the aid of X-ray diffraction analysis, the structure of lobocrasol B (15) was firmly revised as 15a. In *in vitro* bioassays, compound 2 showed moderate antibacterial activities against fish pathogenic bacteria *Streptococcus parauberis* KSP28 and *Phyobacterium damsela* FP2244 with minimum inhibitory concentration (MIC) values of 8.7 and 17.3 µg/mL, respectively. All the steroids exhibited antibacterial activities against the *S. parauberis* KSP28 with MIC values ranging from 12.3 to 53.6 µg/mL. Compounds 2, 7 and 14 have remarkable inhibitory effects on the hemolysin production of *Staphylococcus aureus*, while compounds 8–12 have medium inhibitory effects on the pyocyanin production in *Pseudomonas aeruginosa*.

Keywords: *Lobophytum catalai*; antibacterial activity; soft coral; structural elucidation

1. Introduction

Aquaculture is a crucial component of agriculture, the foundational element of agricultural economic growth, and a crucial source of food. With the rapid and intensive development of aquaculture, many problems related to aquatic animal diseases have gradually been exposed. The main pathogens of aquatic animals include bacteria, viruses, parasites, etc. It is estimated that economic loss of aquatic animals caused by numerous bacteria (such as *Streptococcus parauberis* and *Aeromonas salmonicida*) accounts for 58%, which is the most serious factor leading to the economic loss of aquaculture [1–3]. As antibiotic resistance and drug residues in aquaculture have become global focus, the searching for new and effective antibacterial compounds against fish pathogenic bacteria has become more important and urgent. In addition, bacteria *Staphylococcus aureus* and *Pseudomonas aeruginosa* could also cause a broad range of life-threatening diseases in humans. For example, *S. aureus* cause infectious disease by the production of virulence factors such as hemolysins [4]. Pyocyanin, the secondary metabolite produced by *P. aeruginosa*, is considered to play an essential role of oxidative stress in the infection [5].

Marine invertebrates are important sources of natural products and have been recognized to be the rich source of bioactive secondary metabolites with structural diversity [6–10]. Therefore, the marine invertebrates have enormous potential for exploring new marine drugs. In particular, soft

corals of the genus *Lobophytum* (order Alcyonacea, family Alcyoniidae) have become an intensive research subject, which produced various of structurally intriguing and biologically interesting molecules [11,12]. Extensive literature survey revealed that abundant *Lobophytum* soft corals are inhabiting in the South China Sea, and the titled species *L. catalai* has been rarely studied. Till now, only a total of four studies have been reported on the chemical investigations of this species, leading to the discovery of several terpenes [13–15] and steroids [16] with anti-inflammatory [15] and/or cytotoxic [15] activities.

In the course of our continuing effort to explore chemically fascinating and biologically active secondary metabolites of South China Sea marine invertebrates [12], we have recently carried out a chemical investigation on the soft coral *L. catalai* collected off Yalong Bay, Hainan Province, China, resulting in the isolation and characterization of nine new compounds, namely lobocalines A–I (1–5 and 9–12), together with six known compounds (6–8 and 13–15) (Figure 1). The structural difference between the five new diterpenes 1–5 is reflected in the different positions of substituents. Moreover, the structural diversities of six steroids 9–14 are mainly attributed to the different configurations of C-5 and C-6 in ring B of steroidal nucleus and the variations of functional groups on the side chains. What's more, the structural determinations of new compounds are also a challenging problem, and X-ray diffraction analysis as a powerful tool¹⁷ was applied in this study. Herein, we report the detailed isolation, planar structural elucidation, stereochemistry determination, and antibacterial activities evaluation of these isolated compounds.




Figure 1. Chemical structures of compounds 1–16.

2. Results

Samples of *L. catalai* were frozen immediately to -20°C after collection, and stored at that temperature before they were exhaustively extracted by acetone. The Et₂O-soluble portion of the

acetone extract was subjected to repeated column chromatography (CC) (silica gel, Sephadex LH-20, and reversed-phase HPLC) to yield five new cembrane-type diterpenes lobocalines A–E (**1–5**) and four new steroids lobocalines F–I (**9–12**), along with six known analogues (**6–8** and **13–15**). The known compounds were rapidly characterized as sarcobottgerol D (**6**) [18], 11,12-epoxy-1E,3E,7E-cebratrien-15-ol (**7**) [19], sarcophytol L (**8**) [20], 24 ξ -methylcholestane-3 β ,5 α ,6 β ,25-tetrol-25-monoacetate (**13**) [21], acutumosterol B (**14**) [22], and lobophytol B (**15**) [23], respectively, by the comparison of their NMR data and optical rotation $[\alpha]_D$ values with those reported in the literature.

Compound **1**, namely lobocaline A, was isolated as colorless crystals, gave the molecular formula of $C_{22}H_{34}O_3$ as established by HRESIMS from the protonated molecular ion peak observed at m/z 347.2580 $[M + H]^+$ (calcd. for $C_{22}H_{35}O_3$, 347.2581), implying six degrees of unsaturation. The characteristic peak at ν_{max} 1737 cm^{-1} in its IR spectrum showed the presence of ketone carbonyl group, which was further confirmed by the diagnostic ^{13}C NMR chemical shift at δ_c 170.6. The 1H and ^{13}C NMR data (Tables 1 and 2) of **1** along with the assistance of DEPT spectrum revealed the presence of two trisubstituted double bonds [δ_H 6.06 (1H, d, J = 10.8 Hz, H-2), δ_c 118.6 (CH, C-2) and 146.9 (qC, C-1); δ_H 5.97 (1H, d, J = 10.9 Hz, H-3), δ_c 135.1 (qC, C-4) and 121.7 (CH, C-3)], one exocyclic double bond [δ_H 5.15 (1H, s, H-19) and δ_H 5.18 (1H, s, H-19), δ_c 146.8 (qC, C-8) and 113.0 (CH₂, C-19)] and one epoxy ring [δ_H 2.86 (1H, dd, J = 7.5, 4.6 Hz), δ_c 61.0 (CH, C-11) and δ_c 61.6 (qC, C-12)]. The above-mentioned moieties accounted for five of the six degrees of unsaturation, indicating the monocyclic carbon framework for **1**. A comparison of the NMR data of **1** with those of the co-occurring known compound sarcobottgerol D (**6**) [18], revealed that they were structural analogues, with the only difference being the hydroxyl group at C-7 in **6** was substituted by an acetyloxy group at C-7 in **1**, in agreement with the 42 mass units difference in their molecular weights. The position of the acetyloxy group at C-7, as evidenced by the observation of the upfield shift of C-6 from δ_c 32.9 in **6** to δ_c 30.0 in **1**. This assignment was further confirmed by strong HMBC correlations (Figure 2) from H-7 (δ_H 5.16) to C-19 (δ_c 113.0), C-8 (δ_c 146.8) and carbonyl carbon (δ_c 170.6). Thus, the planar structure of **1** was determined as shown in Figure 2.

The relative configuration of **1** was established mainly by the analysis of NOESY correlations (Figure 2). The clear NOE correlations of H-2 (δ_H 6.06)/H₃-16 (δ_H 1.10), H-2/H₃-18 (δ_H 1.78), and H-3 (δ_H 5.97)/H-5 α (δ_H 2.24), indicated the “1E, 3E” geometry of the two double bonds $\Delta^{1,2}$ and $\Delta^{3,4}$. The highly similar NOE correlations of H-7/H-9 β , H-9 β /H-10 β and H-10 β /H₃-20 between compounds **1** and **6**, suggested that these two compounds shared the same stereochemistry. Furthermore, the suitable single crystals of **1** in MeOH were obtained. The X-ray crystallographic analysis using Cu K α radiation (λ = 1.54178 Å) firmly disclosed the absolute configuration of **1** to be 7R, 11S, 12S with the Flack parameter of 0.00 (10) (Figure 3, CCDC 2290865). What's more, the acetylation of **6** yielding **1** further confirmed the structure and stereo-configuration of **1**. Finally, the chemical structure of **1** was thus established as shown in Figure 1.

Table 1. 1H data of compounds **1–5** in $CDCl_3$.

| No. | 1 ^a | 2 ^b | 3 ^b | 4 ^b | 5 ^a |
|-------------|----------------------------|----------------------------|---------------------------------|----------------------------|----------------------------|
| | δ_H mult. (J in Hz) | δ_H mult. (J in Hz) | δ_H mult. (J in Hz) | δ_H mult. (J in Hz) | δ_H mult. (J in Hz) |
| 2 | 6.06 d (10.8) | 5.95 d (10.19) | 5.94 d (11.4) | 5.92 d (10.1) | 5.89 d (10.0) |
| 3 | 5.97 d (10.9) | 5.93 d (10.38) | 5.92 d (11.5) | 5.98 d (10.1) | 6.08 d (10.0) |
| 5 α | 2.24 m | 2.13 m | 2.26 m | 4.12 dd (10.7, 3.5) | 5.23 ov |
| 5 β | 2.14 m | 2.33 m | 2.44 dd (13.1, 3.2) | | |
| 6 α | 2.02 m | 1.87 m | 4.54 ddd (11.6, 9.0, 3.2) | 2.39 ddd (13.5, 10.7, 8.9) | 2.53 dt (15.0, 7.5) |
| 6 β | 1.93 ddq (14.4, 10.0, 4.8) | 1.83 m | | 2.31 m | 1.27 m |
| 7 | 5.16 ov | 5.22 t (6.8) | 5.30 dt (9.0, 1.5) | 5.19 t (7.7) | 5.25 dd (8.5, 6.3) |
| 9 α | 2.26 m | 2.36 m | 2.30 m | 2.25 m | 2.14 m |
| 9 β | 2.23 m | 2.06 m | 2.21 m | 2.12 m | 1.38 m |
| 10 α | 1.79 m | 1.98 m | 1.72 ddt (14.6, 13.1, 3.6) | 1.64 m | 1.52 m |
| 10 β | 1.65 dp (13.8, 6.9) | 1.61 m | 1.46 dddd (14.6, 8.3, 4.8, 3.4) | 1.60 m | 1.81 dq (10.1, 5.9) |
| 11 | 2.86 dd (7.5, 4.6) | 3.05 m | 2.82 dd (8.4, 3.6) | 2.80 t (6.3) | 2.89 dd (7.3, 5.3) |
| 13 α | 2.11 m | 2.19 m | 1.67 ddd (15.2, 6.6, 4.1) | 1.98 ddd (14.8, 8.9, 6.2) | 2.10 m |

| | | | | | |
|------|---------------------------|--------------|----------------------------|---------------------|---------------------|
| 13β | 1.41 dt (13.4, 5.4) | 1.13 m | 2.00 ddd (15.0, 10.5, 4.4) | 1.64 m | 1.42 dt (13.8, 6.2) |
| 14α | 2.41 ddd (13.8, 9.9, 5.6) | 2.24 m | 2.36 m | 2.26 m | 2.10 m |
| 14β | 2.08 m | 2.20 m | 1.87 m | 1.92 dt (13.1, 6.2) | 1.51 m |
| 15 | 2.33 q (6.8) | 2.31 m | 2.31 m | 2.32 m | 2.33 m |
| 16 | 1.10 d (6.8) | 1.05 d (6.8) | 1.05 d (6.8) | 1.05 d (6.8) | 1.04 d (6.9) |
| 17 | 1.03 d (6.8) | 1.03 d (6.9) | 1.02 d (6.9) | 1.03 d (6.7) | 1.02 d (6.9) |
| 18 | 1.78 s | 1.72 s | 1.78 s | 1.74 s | 1.72 s |
| 19α | 5.15 ov | 5.11 s | 1.57 s | 1.57 s | 1.63 s |
| 19β | 5.18 ov | 5.05 s | | | |
| 20 | 1.21 s | 1.25 s | 1.25 s | 1.25 s | 1.25 s |
| -OAc | 2.05 s | 2.07 s | | | 2.06 s |

^a Recorded at 600 MHz; ^b Recorded at 800 MHz

Table 2. ¹³C (150 MHz) data of compounds 1–5 in CDCl₃.

| No. | 1 | 2 | 3 | 4 | 5 |
|-----|------------------------|------------------------|-----------------------|-----------------------|-----------------------|
| | δ _c , type | δ _c , type | δ _c , type | δ _c , type | δ _c , type |
| 1 | 146.9, C | 147.7, C | 147.7, C | 149.6, C | 149.9, C |
| 2 | 118.6, CH | 118.2, CH | 118.3, CH | 117.9, CH | 117.7, CH |
| 3 | 121.7, CH | 121.5, CH | 123.4, CH | 122.8, CH | 123.2, CH |
| 4 | 135.1, C | 135.6, C | 132.4, C | 136.4, C | 133.0, C |
| 5 | 34.9, CH ₂ | 34.0, CH ₂ | 48.5, CH ₂ | 78.1, CH | 77.1, CH |
| 6 | 30.0, CH ₂ | 31.1, CH ₂ | 67.6, CH | 34.2, CH ₂ | 30.1, CH ₂ |
| 7 | 72.5, CH | 75.9, CH | 130.2, CH | 122.3, CH | 120.5, CH |
| 8 | 146.8, C | 147.6, C | 137.4, C | 135.8, C | 136.6, C |
| 9 | 31.5, CH ₂ | 28.8, CH ₂ | 37.1, CH ₂ | 36.9, CH ₂ | 37.1, CH ₂ |
| 10 | 26.8, CH ₂ | 28.0, CH ₂ | 24.6, CH ₂ | 24.8, CH ₂ | 24.9, CH ₂ |
| 11 | 61.0, CH | 62.4, CH | 59.1, CH | 59.5, CH | 60.5, CH |
| 12 | 61.6, C | 61.7, C | 61.0, C | 60.9, C | 61.4, C |
| 13 | 37.1, CH ₂ | 38.8, CH ₂ | 34.0, CH ₂ | 35.0, CH ₂ | 37.0, CH ₂ |
| 14 | 26.0, CH ₂ | 26.1, CH ₂ | 23.4, CH ₂ | 24.2, CH ₂ | 25.4, CH ₂ |
| 15 | 33.2, CH | 34.2, CH | 32.5, CH | 33.2, CH | 34.1, CH |
| 16 | 21.5, CH ₃ | 22.2, CH ₃ | 22.3, CH ₃ | 22.2, CH ₃ | 22.2, CH ₃ |
| 17 | 23.1, CH ₃ | 22.3, CH ₃ | 23.0, CH ₃ | 22.8, CH ₃ | 22.3, CH ₃ |
| 18 | 16.7, CH ₃ | 17.8, CH ₃ | 17.6, CH ₃ | 11.3, CH ₃ | 14.5, CH ₃ |
| 19 | 113.0, CH ₂ | 111.9, CH ₂ | 15.7, CH ₃ | 15.1, CH ₃ | 15.5, CH ₃ |
| 20 | 18.8, CH ₃ | 17.2, CH ₃ | 19.4, CH ₃ | 18.9, CH ₃ | 18.0, CH ₃ |
| OAc | 170.6, C | 170.4, C | | | 170.5, C |
| | 21.4, CH ₃ | 21.3, CH ₃ | | | 21.5, CH ₃ |




Figure 2. The ^1H - ^1H COSY, selected key HMBC and ROESY correlations of compounds **1**-**5**.




Figure 3. Perspective ORTEP drawing of the X-ray structure of **1**.

Lobocaline B (**2**), a colorless oil, gave the same molecular formula as **1** on basis of its HRESIMS ion peak at m/z 347.2581 $[\text{M} + \text{H}]^+$ (calcd. for $\text{C}_{22}\text{H}_{35}\text{O}_3$, 347.2581). Overall, the ^1H and ^{13}C NMR data of **2** (Tables 1 and 2) were reminiscent of **1**. Careful comparison of their NMR data revealed they possessed the same planar structure and only chemical shifts at C-7 (δ_{C} 72.5 in **1** vs δ_{C} 75.9 in **2**) were different, suggesting that **2** was simply the C-7 epi-isomer of **1**, further analysis of 2D NMR spectra confirmed this hypothesis (Figure 2). As a consequence, we regard the structure and absolute configuration of **2** as depicted in Figure 1.

Lobocaline C (**3**) was isolated as a colorless oil, and its molecular formula was assigned as $\text{C}_{20}\text{H}_{32}\text{O}_2$ by HRESIMS ion peak at m/z 327.2295 $[\text{M} + \text{Na}]^+$ (calcd. for $\text{C}_{20}\text{H}_{32}\text{O}_2\text{Na}$, 327.2295), indicating five degrees of unsaturation. The 1D NMR data of **3** (Tables 1 and 2) showed great similarities to those of 1E,3E,7E,11:12-epoxy-1,3,7-cembratriene, a known cembranoid isolated from the South Andaman Coast soft coral *Lobophytum* sp. [24], with the only difference being the presence of an additional hydroxyl group at C-6 in **3**, in agreement with the 16 mass units difference between these two compounds. This assignment was further confirmed by the strong ^1H - ^1H COSY correlations of H-6 (δ_{H} 4.54)/H-7 (δ_{H} 5.30) (Figure 2). As mentioned above, the planar structure of **3** was determined as shown in Figure 2. The geometries of the double bonds at $\Delta^{1,2}$, $\Delta^{3,4}$ and $\Delta^{7,8}$ were both assigned to

be **3** by the NOESY correlations of H-2 (δ_{H} 5.94)/H₃-16 (δ_{H} 1.05), H-2/H₃-18 (δ_{H} 1.78), and H-7 (δ_{H} 5.30)/H-9 α (δ_{H} 2.30) (Figure 2), respectively. The relative configurations of C-11 and C-12 in **3** were proven to be the same as those of **1** due to the diagnostic NOESY correlations of H₃-20 (δ_{H} 1.25)/H-10b (δ_{H} 1.46), H₃-20/H-13b (δ_{H} 2.00), H-11 (δ_{H} 2.82)/H-3 (δ_{H} 5.92), and H-11/H-14a (δ_{H} 2.36). To figure out the relative configuration of **3**, the QM-NMR calculation was performed to give the best match of more than 99% probability in DP4+ with the 6R*, 11S*, 12S* isomer (see the details in Supplementary Material). The absolute configuration of **3** was determined by time dependent density functional theory (TDDFT) ECD calculation. The theoretical ECD spectrum of **3** was calculated by the DFT method at B3LYP/6-311G(d,p) level. As a result, the Boltzmann-averaged ECD spectrum of (6R, 11S, 12S)-**3** highly matched to the experimental ECD spectrum of **3**, while the calculated ECD spectrum of enantiomer showed completely opposite curve (Figure 4). Consequently, the absolute configuration of **3** was established to be 6R, 11S, 12S.




Figure 4. Experimental ECD spectrum of **3** (black), calculated ECD spectra of the enantiomers (6R, 11S, 12S)-**3** (red) and (6S, 11R, 12R)-**3** (blue).

Lobocaline D (**4**), a colorless oil, has the same molecular formula ($\text{C}_{20}\text{H}_{32}\text{O}_2$) as those of **3**, implying they are isomers. Comparison of ^1H and ^{13}C chemical shifts of **4** and **3** (Tables 1 and 2) followed by a detailed analysis of 2D NMR data revealed the structure of **4** was similar to that of **3** with different substituted position of the hydroxyl group. This conclusion was further supported by HMBC correlations from H₃-18 (δ_{H} 1.74) to C-5 (δ_{C} 78.1) and ^1H - ^1H COSY correlations of H-5 (δ_{H} 4.12)/H-6 α (δ_{H} 2.39)/H-7 (δ_{H} 5.19). Thus, the planar structure of **4** was determined. The relative configurations of C-11 and C-12 in **4** were assigned to be the same as those of **1** due to the similar ^{13}C NMR data. Similarly, the relative configuration of **4** was also elucidated via QM-NMR calculations by using the DP4+ protocol. The best match was observed for the 5R*, 11S*, 12S* relative configuration with a DP4+ probability over 99%. Moreover, the absolute configuration of **4** was further determined by TDDFT-ECD approach. As shown in Figure 5, the Boltzmann-averaged ECD curve calculated for the (5S, 11R, 12R)-**4** enantiomer matched very well with the experimental ECD spectrum of **4**. Accordingly, the absolute configuration of **4** was determined to be 5S, 11R, 12R.




Figure 5. Experimental ECD spectrum of **4** (black), calculated ECD spectra of the enantiomers (5S, 11R, 12R)-**4** (red) and (5R, 11S, 12S)-**4** (blue).

Lobocaline E (**5**) was obtained as a colorless oil. Its molecular formula, $C_{22}H_{34}O_3$, was deduced from the ion peak observed at m/z 369.2397 $[M + Na]^+$ (calcd. for $C_{22}H_{34}O_3Na$, 369.2400) in its HRESIMS spectrum. The 1H and ^{13}C NMR data (Tables 1 and 2) of **5** were extremely similar to those of the co-occurring compound **4**, indicating that they are structural analogues. In fact, the only difference between these two compounds was the replacement of the hydroxyl group at C-5 in **4** by the acetyl group at C-5 in **5**, in agreement with the 42 mass units difference between compounds **4** and **5**. To determine the relative configuration of **5**, the theoretical and experimental NMR data were correlated and their corresponding DP4+ probabilities were estimated. Consequently, the candidate structure **5a** (Figure S11.3) showed the dominant probability of 99.52%, indicating the 5R*, 11S*, 12S* relative configuration of **5**. In this case, TDDFT-ECD calculation was also employed to determine the absolute stereochemistry of **5**. As shown in Figure 6, the calculated ECD spectrum of (5S, 11R, 12R)-**5** fairly matched with the experimental one, allowing us to assign the absolute configuration of **5** to be 5S, 11R, 12R. Moreover, the hydrolysis reaction of **5** was also performed, but unfortunately, no product was detected due to the low amount of isolated compound. Finally, the chemical structure of **5** was thus established as depicted in Figure 1.




Figure 6. Experimental ECD spectrum of **5** (black), calculated ECD spectra of the enantiomers (5S, 11R, 12R)-**5** (red) and (5R, 11S, 12S)-**5** (blue).

Lobocaline F (**9**) was isolated as a white powder. Its molecular formula was determined as $C_{29}H_{50}O_6$ by HRESIMS m/z 517.3504 $[M + Na]^+$ (calcd. for $C_{29}H_{50}O_6Na$, 517.35), appropriate for five degrees of unsaturation. The 1H NMR data of **9** (Table 3) showed the general characters of polyhydroxylated sterols, including an olefinic proton resonated at δ_H 5.70 (1H, dd, $J = 3.5, 1.5$ Hz, H-16), two oxymethines at δ_H 4.27 (1H, s, H-3), 3.82 (1H, dd, $J = 12.2, 4.9$ Hz, H-6), a hydroperoxyl group signal at δ_H 9.20 (br s), and seven methyls at δ_H 0.94 (3H, s, Me-18), 0.95 (3H, s, Me-19), 1.30 (3H, s, Me-21), 1.20 (3H, s, Me-26), 1.19 (3H, s, Me-27), 0.86 (3H, d, $J = 7.3$ Hz, Me-28), 0.93 (3H, d, $J = 7.1$ Hz, Me-29). Moreover, the ^{13}C NMR data (Table 3) and DEPT spectrum of **9** indicated the presence of 29 signals, which composed of seven methyls, eight methylenes, eight methines (including one olefinic at δ_C 126.9, and seven sp^3 hybridized at δ_C 67.9, 72.0, 32.5, 43.5, 58.0, 30.2, 50.3), and six quaternary carbons (including an olefinic at δ_C 158.3 and five sp^3 hybridized at δ_C 78.2, 41.3, 47.5, 85.7, 75.6). These above data suggested the presence of a trisubstituted double bond, which accounted for one degree of unsaturation. The remaining four degrees of unsaturation were attributed to a tetracyclic system in the molecule. In the 1H - 1H COSY spectrum, it was possible to identify three different structural units extending from C-1 to C-4; from C-6 to both C-12 and C-16 through C-8; and from C-22 to both C-28 and C-29 through C-23 (Figure 7). From the HMBC spectrum, the correlations from H₃-19 to C-1, C-5, C-9 and C-10; from H₃-18 to C-12, C-13, C-14 and C-17; from H-6 to C-4 and C-5; from H-16 to C-20; from H₃-21 to C-17, C-20 and C-22; from both H₃-26 and H₃-27 to C-24; and from H₃-28 to C-25 permitted the establishment of the carbon skeleton of a 23,24-dimethylcholestane (Figure 7). The hydroperoxyl group substituted at C-20 was confirmed by the HMBC correlation of the hydroperoxyl proton δ_H 9.20 (br s) to the oxygenated carbon at δ_C 86.1 (C-20). Extensive literature survey revealed that the structure of **9** closely resembled that of michosterols A (**16**), a polyoxygenated steroid isolated from the soft coral *Lobophytum michaelae* [25]. A comparison of the NMR data of **9** with **16**, revealed that they were structural analogues, and the only difference occurred at the position C-25, where the acetyloxy group in **16** was replaced by a hydroxyl group in **9**, in agreement with the 42 mass units difference between compounds **9** and **16**. As mentioned above, the planar structure of **9** was thus established.

Table 3. 1H (600 MHz) and ^{13}C (150 MHz) NMR data of compounds **9** and **10** in $CDCl_3$.

| No. | 9 | | 10 | |
|-----|-----------------------|------------------------------|-----------------------|------------------------------|
| | δ_C , type | δ_H mult (J in Hz) | δ_C , type | δ_H mult (J in Hz) |
| 1 | 25.4, CH ₂ | 1.35 m 1.81 m | 25.4, CH ₂ | 1.36 m 1.83 m |
| 2 | 27.9, CH ₂ | 1.65 m 1.56 m | 28.0, CH ₂ | 2.09 m 1.58 m |
| 3 | 67.9, CH | 4.27 br s | 67.9, CH | 4.28 br s |
| 4 | 30.1, CH ₂ | 1.97 m 1.84 m | 30.1, CH ₂ | 1.85 m 1.96 m |
| 5 | 78.2, C | | 78.2, C | |
| 6 | 72.0, CH | 3.82 dd (12.2, 4.9) | 72.0, CH | 3.82 dd (12.2, 4.9) |
| 7 | 34.7, CH ₂ | 1.85 m 1.07 m | 34.7, CH ₂ | 1.86 m 1.07 m |
| 8 | 32.5, CH | 1.77 m | 32.6, CH | 1.76 m |
| 9 | 43.5, CH | 1.35 m | 43.6, CH | 1.30 m |
| 10 | 41.3, C | | 41.3, C | |
| 11 | 21.7, CH ₂ | 1.49 m 1.40 m | 21.8, CH ₂ | 1.48 m 1.53 m |
| 12 | 36.2, CH ₂ | 2.08 m 1.67 m | 36.5, CH ₂ | 2.11 m 1.53 m |
| 13 | 47.5, C | | 47.9, C | |
| 14 | 58.0, CH | 1.51 m | 57.9, CH | 1.47 m |
| 15 | 31.2, CH ₂ | 1.87 m 2.11 m | 31.1, CH ₂ | 1.83 m 2.07 m |
| 16 | 126.9, CH | 5.70 dd (3.5, 1.5) | 123.6, CH | 5.49 dd (3.4, 1.5) |
| 17 | 158.3, C | | 161.2, C | |
| 18 | 18.1, CH ₃ | 0.94 s | 18.0, CH ₃ | 0.96 s |
| 19 | 19.4, CH ₃ | 0.95 s | 18.1, CH ₃ | 0.96 s |
| 20 | 85.7, C | | 75.7, C | |

| | | | | |
|-----|-----------------------|--------------|-----------------------|--------------|
| 21 | 23.0, CH ₃ | 1.30 s | 29.3, CH ₃ | 1.39 s |
| 22 | 46.7, CH ₂ | 2.04 m | 50.6, CH ₂ | 1.65 m |
| | | 1.48 m | | 1.40 m |
| 23 | 25.2, CH | 1.36 m | 27.9, CH | 2.10 m |
| 24 | 50.3, CH | 1.70 m | 47.3, CH | 1.99 m |
| 25 | 75.6, C | | 86.6, C | |
| 26 | 30.2, CH ₃ | 1.20 s | 22.9, CH ₃ | 1.98 s |
| 27 | 25.2, CH ₃ | 1.19 s | 23.8, CH ₃ | 1.46 s |
| 28 | 10.8, CH ₃ | 0.86 d (7.3) | 8.8, CH ₃ | 0.85 d (7.2) |
| 29 | 17.3, CH ₃ | 0.93 d (7.1) | 17.3, CH ₃ | 0.90 d (6.9) |
| OAc | | | 170.6, C | |
| | | | 25.1, CH ₃ | 1.50 s |
| OOH | | 9.20 br s | | |

The relative configuration of **9** was established mainly by analysis of the NOESY correlations. As depicted in Figure 7, it was found that the NOE interactions displayed by both H₃-18/H-8, H₃-19/H-8, H₃-19/H-6, and H-6/H-8, assuming the β -orientation of H₃-19, H-6, H-8 and H₃-18. Moreover, the NOESY correlation of H-9/H-14 assigned the α -orientation of H-9 and H-14. Further, the chemical shifts of C-20, C-21, C-22, C-23, C-28 and C-29 on the side chain are similar to that of **16**, suggested the same relative configuration of the chair centers on the side chain. In addition, the stereochemistry of C-5 and C-6 was assigned to be 5S*, 6S* by the comparison of chemical shifts of C-5 (δ_c 78.4) and C-6 (δ_c 73.2) with the model known compound 5 β -cholestane-3 β ,5,6 α -triol [26,27]. Consequently, the relative configuration of **9** was determined. Since it has been known for quite a long time that both H₃-18 and H₃-19 should be positioned on the β -face for natural steroids, thus the absolute configuration of **9** was elucidated as shown in Figure 1.




Figure 7. The ¹H-¹H COSY, selected key HMBC and NOESY correlations of compounds **9**–**12**.

Lobocaline G (**10**) was isolated as a white powder with the molecular formula of C₃₁H₅₂O₆ on the basis of HRESIMS ion peak at *m/z* 543.3655 [M + Na]⁺ (calcd. for C₃₁H₅₂O₆Na, 543.3656), corresponding to six degrees of unsaturation. The ¹³C NMR and DEPT spectra of **10** displayed 31 carbon signals including eight methyls, eight methylenes, eight methines (including one olefinic at δ_c 123.6), and seven quaternary carbons (including an olefinic at δ_c 161.2 and one carbonyl at δ_c 170.6), which accounting for two out of six degrees of unsaturation, thus requiring four extra rings in the molecule structure of **10**. The ¹³C NMR data (Table 3) of **10** closely resembled that of michosterols A (**16**) [25], suggested that they were also structural analogues. In fact, the only difference between **10** and **16** was appeared at the C-20, where the hydroperoxyl group in **16** was substituted by a

hydroxyl group in **10**, in agreement with a 16 mass units difference between their molecular weights. This assignment was supported by not only the carbon chemical shift of C-20 significantly upfield shifted from δ_c 85.6 ppm to δ_c 75.7 ppm, but also the chemical shift of the distinctive olefinic proton H-16 shifted from δ_H 5.70 (d, $J = 2.0$ Hz) to δ_H 5.49 (dd, $J = 3.4, 1.5$ Hz). The relative stereochemistry of **10** was determined by the analysis of NOE correlations (Figure 7) and by comparison of NMR spectroscopic data with those of model molecule sarcophytosterol, a known steroid isolated from the Dongsha atoll soft coral *Lobophytum sarcophytoides*, whose structure has been unambiguously determined by X-ray diffraction analysis [28]. On the basis of the above findings, the structure of compound **10** was determined as shown in Figure 1.

The molecular formula of lobocaline H (**11**) was the same as michosterols A (**16**), which was determined by HRESIMS ion peak at m/z 559.3609 $[M + Na]^+$ (calcd. for $C_{31}H_{52}O_7Na$, 559.3605). The proton and carbon resonances of **11** showed a high degree of similarity to those of **16**. By comparison of the 1H and ^{13}C NMR data (Table 4) of **11** and **16**, the differences were found in the chemical shifts of carbons in rings A and B [C-1 (δ_c 32.3), C-2 (δ_c 31.0), C-4 (δ_c 40.8), C-5 (δ_c 76.3) and C-6 (δ_c 76.2) in **11** and C-1 (δ_c 25.2), C-2 (δ_c 27.7), C-4 (δ_c 30.0), C-5 (δ_c 78.1) and C-6 (δ_c 71.8) in **16**]. The following detailed analysis of 1H - 1H COSY and HMBC correlations assigned the planar structure of **11**, the same as **16**, which suggested that **11** was the isomer of **16**. Literature checking revealed that the NMR data of rings A and B in **11** were strongly reminiscent of the known compound 23,24-dimethylcholest-16-ene-3 β ,5 α ,6 β ,11 α ,20(R)-pentol-3-monoacetate [29], indicating that the rings' structures were identical. Thus, the absolute stereochemistry of C-3, C-5, and C-6 in **11** was speculatively assigned as 3S, 5R, 6R.

Table 4. 1H (600 MHz) and ^{13}C (150 MHz) NMR data of compounds **11** and **12** in $CDCl_3$.

| No. | 11 | | 12 | |
|-----|-----------------------|---------------------------|-----------------------|--------------------------------------|
| | δ_c , type | δ_H mult (J in Hz) | δ_c , type | δ_H mult (J in Hz) |
| 1 | 32.3, CH ₂ | 1.56 m 1.42 m | 32.4, CH ₂ | 1.53 m 1.42 m |
| 2 | 31.0, CH ₂ | 1.86 m 1.52 m | 31.0, CH ₂ | 1.88 m 1.52 m |
| 3 | 67.7, CH | 4.11td (10.8,5.3) | 67.7, CH | 4.11 td (10.9, 5.3) |
| 4 | 40.8, CH ₂ | 2.10 m 1.62 m | 40.9, CH ₂ | 2.10 m 1.64 m |
| 5 | 76.3, C | | 76.4, C | |
| 6 | 76.2, CH | 3.57 t (3.1) | 76.2, CH | 3.60 t (2.9) |
| 7 | 34.4, CH ₂ | 1.70 m 1.61 m | 34.5, CH ₂ | 1.73 ddd (14.1, 12.5, 3.7) 1.63 m |
| 8 | 29.0, CH | 1.98 m | 29.0, CH | 1.96 m |
| 9 | 46.1, CH | 1.34 m | 46.2, CH | 1.32 td (11.4, 5.0) |
| 10 | 38.6, C | | 38.7, C | |
| 11 | 21.3, CH ₂ | 1.45 m 1.37 m | 21.3, CH ₂ | 1.41 m 1.45 m |
| 12 | 36.1, CH ₂ | 1.67 m 2.07 m | 36.5, CH ₂ | 1.58 m 2.09 m |
| 13 | 47.6, C | | 47.9, C | |
| 14 | 57.7, CH | 1.52 m | 57.5, CH | 1.45 m |
| 15 | 31.1, CH ₂ | 2.13 m 1.90 m | 31.0, CH ₂ | 2.07 m 1.90 m |
| 16 | 127.1, CH | 5.70 dd (3.5, 1.5) | 123.7, CH | 5.49 dd (3.4, 1.5) |
| 17 | 157.8, C | | 161.2, C | |
| 18 | 18.3, CH ₃ | 0.98 s | 18.4, CH ₃ | 1.00 s |
| 19 | 16.9, CH ₃ | 1.21 s | 16.9, CH ₃ | 1.22 s |
| 20 | 86.1, C | | 75.8, C | |
| 21 | 22.9, CH ₃ | 1.32 s | 29.3, CH ₃ | 1.39 s |
| 22 | 44.6, CH ₂ | 1.96 m 1.43 m | 50.5, CH ₂ | 1.62 m 1.43 m |
| 23 | 26.6, CH | 2.07 m | 28.0, CH | 2.10 m |
| 24 | 46.4, CH | 2.23 qd (7.6, 1.9) | 47.3, CH | 1.95 m |
| 25 | 87.2, C | | 86.6, C | |
| 26 | 24.3, CH ₃ | 1.42 s | 23.9, CH ₃ | 1.47 s |

| | | | | |
|-----|-----------------------|--------------|-----------------------|--------------|
| 27 | 25.8, CH ₃ | 1.49 s | 25.1, CH ₃ | 1.49 s |
| 28 | 9.4, CH ₃ | 0.88 d (7.2) | 8.8, CH ₃ | 0.85 d (7.1) |
| 29 | 18.1, CH ₃ | 0.93 d (6.9) | 17.9, CH ₃ | 0.90 d (6.9) |
| OAc | 171.9, C | | 170.6, C | |
| | 22.7, CH ₃ | 2.02 s | 22.9, CH ₃ | 1.98 s |
| OOH | | 7.89 br s | | |

Lobocaline I (**12**), which was obtained as a white powder, gave the molecular formula C₃₁H₅₂O₆ on basis of its HRESIMS ion peak at m/z 543.3653 [M + Na]⁺ (calcd. for C₃₁H₅₂O₆Na, 543.3656), 16 mass units less than that of **11**. A comparison of the NMR data of **12** with **11** (Table 4), revealed that they were structural analogues, with the only difference being the presence of a hydroxyl group substituted at C-20 on the side chain of **12** instead of a hydroperoxyl group in **11**, in agreement with the 16 mass units difference between compounds **11** and **12**. The hydroxyl group was substituted at C-20, as evidenced by the observation of the upfield shifting of C-20 from δ_c 86.1 in **11** to δ_c 75.8 in **12**. Similarly, the relative configuration of **12** was determined by analyzing NOE correlations and comparing its NMR data with those of compounds **10** and **11**. As mentioned above, the structure of **12** was assigned as shown in Figure 1.

Compound **15** was readily identified as lobophytrol B, a capnosane-type diterpenoid previously reported to be isolated from *Lobophytum* sp. by our group [21]. By comparing the nuclear magnetic and optical rotation data, they are exactly the same. In this study, the suitable crystals of **15** have been eventually obtained, which was then sent for X-ray crystallographic analysis using Cu K α radiation ($\lambda = 1.54178$ Å). Analysis of the X-ray data unambiguously determined the planar structure and absolute configuration of **15** with the Flack parameter of 0.12 (7) (CCDC 2290866). Surprisingly, the X-ray result disclosed that the correct structure of lobophytrol B is **15a**, instead of **15** (Figure 8). Compared to the mass spectrum, the molecular weight is 18 more than before, probably due to the presence of different molecular fragmentation peaks. We carefully and in-depth analyzed the data to determine why the structure of **15** was incorrectly signed, realizing that the error was triggered by the chemical shift of carbon substituted by hydroxyl group and the same oxygen ring established at positions C-8 and C-12, as well as the existence of various molecular fragment peaks in the mass spectrum. Careful re-examination of the HRESIMS spectrum revealed wrong identification of the molecular ion peak at m/z HREIMS 363.2517 [M + Na]⁺ (calcd for C₂₀H₃₆O₄Na, 363.2506), while the cluster of quasi-molecular ion peaks centered at m/z 323.2581 [M + H]⁺ (calcd for C₂₀H₃₅O₃, 323.2581) was overlooked (Figure S10.1).




Figure 8. Revised structure (**15a**) and originally structure of lobophytrol B (**15**).

In *in vitro* bioassay, the isolated compounds were tested for their antibacterial, cytotoxic and anti-inflammatory effects. In the antibacterial bioassays (Table 5), compound **2** showed moderate antibacterial activities against the fish pathogenic bacteria *Streptococcus parauberis* KSP28 (MIC 8.7 μ g/mL) and *Phyobacterium damsela* FP2244 (MIC 17.3 μ g/mL). Compounds **7–9** showed weak antibacterial activities against *S. parauberis* KSP28 (MIC 30.4, 32.2, 49.4 μ g/mL) and *P. damsela* FP2244 (MIC 30.4, 16.1, 49.4 μ g/mL). All the steroids exhibited antibacterial activities against *S. parauberis* KSP28 with MIC values ranging from 12.3 to 53.6 μ g/mL. Besides, compounds **10** and **13**

exhibited significant antibacterial activities against a variety of strains, especially compound **13** displayed potent inhibitory activity against *P. damsela* FP2244, *S. parauberis* SPOF3K and *S. agalactiae* WR10 with MIC value of 6.2 µg/mL, 12.3 µg/mL and 12.3 µg/mL, respectively. Furthermore, compound **13** showed the growth inhibitory activities against the vancomycin-resistant *Enterococcus faecium* G1 and G8 with the MIC values of 12.3 µg/mL and 12.3 µg/mL, respectively, comparable with that of positive control levofloxacin hydrochloride (MIC > 39.78 µg/mL), ampicillin sodium (MIC > 37.14 µg/mL) and vancomycin hydrochloride (MIC > 297 µg/mL and 74.25 µg/mL).

In hemolytic activity, the results showed that the hemolytic activity of *S. aureus* treated with compounds **1–4**, **6–8** and **13–15** were obviously reduced when compared with the control (without compound treatment). In particular, the hemolysis percentage of compounds **2**, **7** and **14** test groups reached about 35.7%, 42.2% and 39.1% (Figure 9). These results suggest that compounds **2**, **7** and **14** have a strong inhibitory effect on the hemolysin production of *S. aureus*. Furthermore, in the pyocyanin quantitation assay experiment (Figure 10), compounds **8–12** have medium inhibition effects on the pyocyanin production in *P. aeruginosa*, compared with the control (without compound treatment).




Figure 9. Efficacy of compounds **1–4**, **6–8** and **13–15** in inhibiting the hemolytic activity of *S. aureus*. ** $p<0.01$, * $p<0.05$. The assays were independently repeated at least three times.




Figure 10. Efficacy of compounds **1**, **3–4** and **6–15** in the pyocyanin production of *P. aeruginosa*. ** $p<0.01$, * $p<0.05$. The assays were independently repeated at least three times.

Table 5. The MIC values ($\mu\text{g/mL}$) of antibacterial bioassays of compounds 2 and 7–14.

| | <i>Streptococcus</i> | <i>Enterococcus</i> | <i>Aeromonas</i> | <i>Photobacterium</i> | <i>Streptococcus</i> | <i>Lactococcus</i> | <i>Phycoerythrin</i> | <i>Enterococcus</i> | <i>Enterococcus</i> | <i>Enterococcus</i> | <i>Enterococcus</i> | <i>Enterococcus</i> | <i>Streptococcus</i> | <i>Edwardsiella</i> |
|----------|----------------------|---------------------|------------------|-----------------------|----------------------|--------------------|----------------------|---------------------|---------------------|---------------------|---------------------|---------------------|----------------------|---------------------|
| Compound | <i>S. parvus</i> | 5270 | MDR8 | AS42 | halotolerans | SPOF3K | MP5245 | G1 | G4 | G7 | G8 | G13 | agala | piscicidal |

| | KSP2 | | | LMG | | | FP224 | | | | | | | | |
|-----------------|------|----------------|--------|--------|--------|------|-------|--------|--------|--------|--------|--------|------|------|------|
| | 8 | | | 22194T | | | 4 | | | | | | | | |
| 2 | 8.7 | - ^b | - | - | - | - | 17.3 | - | - | - | - | - | - | - | - |
| 7 | 30.4 | - | - | - | - | - | 30.4 | - | - | - | - | - | - | - | - |
| 8 | 32.2 | - | - | - | - | - | 16.1 | - | - | - | - | - | - | - | - |
| 9 | 49.4 | - | - | - | - | - | 49.4 | - | - | - | - | - | - | - | 49.4 |
| 10 | 13.0 | - | 26.0 | - | 26.0 | 52.0 | 13.0 | 52.0 | 52.0 | 26.0 | 52.0 | 52.0 | 26.0 | - | - |
| 11 | 53.6 | - | - | - | - | - | - | - | - | 53.6 | - | - | - | - | - |
| 12 | 26.0 | - | - | - | 26.0 | - | 26.0 | - | - | 52.0 | 52.0 | - | 52.0 | 52.0 | - |
| 13 | 12.3 | 49.2 | 24.6 | 24.6 | 12.3 | 24.6 | 6.2 | 12.3 | 49.2 | 24.6 | 12.3 | 49.2 | 12.3 | - | - |
| 14 | 50.8 | - | - | - | 50.8 | - | - | - | - | - | - | - | - | - | - |
| TC ^a | 3.01 | >48.09 | 6.11 | 0.19 | >24.05 | 0.38 | 0.02 | 0.09 | 0.19 | 0.09 | 0.09 | 12.00 | 0.75 | 1.50 | - |
| OT | 1.55 | >49.69 | 0.39 | 0.39 | 12.42 | 0.19 | 0.02 | 0.19 | 0.19 | 0.09 | 0.05 | 6.20 | 0.78 | 0.78 | - |
| LF | 1.24 | 4.98 | 0.31 | 0.16 | 1.24 | 0.62 | 0.02 | >39.78 | >39.78 | >39.78 | 39.78 | >39.78 | 2.49 | 0.62 | - |
| AMP | 4.64 | >37.14 | >18.57 | 0.04 | 0.58 | 0.58 | 0.02 | >37.14 | >37.14 | >37.14 | >37.14 | >37.14 | 1.16 | 9.28 | - |
| VAN | | | | | | | | >297 | >297 | 18.56 | 74.25 | >297 | <0.2 | >148 | - |

^a Tetracycline hydrochloride (TC), oxytetracycline hydrochloride (OT), levofloxacin hydrochloride (LF), Ampicillin (AMP), and Vancomycin hydrochloride (VAN) were used as positive controls. ^b '-' indicated they were not subjected to the antibacterial rescreening experiments since their inhibition rates against these bacteria were < 90% in the preliminary antibacterial bioassays.

3. Materials and methods

3.1. General Experimental Procedures

Melting points were measured on an X-4 digital micro melting point apparatus. Optical rotations were measured on a Perkin-Elmer 241MC polarimeter (PerkinElmer, Fremont, CA, USA). IR spectra were measured on a Nicolet 6700 spectrometer (Thermo Scientific, Waltham, MA, USA), peaks are reported in cm^{-1} . NMR spectra were measured in CDCl_3 with a Bruker DRX 400, 500, 600 and 800 MHz spectrometer (Bruker Biospin AG, Fällanden, Germany). Chemical shifts are reported in parts per million (δ) in CDCl_3 (δ_{H} reported referred to CHCl_3 at 7.26 ppm; δ_{C} reported referred to CDCl_3 at 77.2 ppm), and coupling constants (J) are expressed in Hz. HRESIMS spectra were recorded on an Agilent 1290-6545 UHPLC-QTOF mass spectrometer. Commercial silica gel (Qingdao Haiyang Chemical Group Co., Ltd., Qingdao, China, 200–300 and 300–400 mesh), Sephadex LH-20 gel (Amersham Biosciences) were used for column chromatography, and precoated silica gel plates (Yan Tai Zi Fu Chemical Group Co., Yantai, China, G60 F-254) were used for analytical TLC. Reversed-phase (RP) HPLC was performed on an Agilent 1260 series liquid chromatography equipped with a DAD G1315D detector at 210 and 254 nm. A semi-preparative ODS-HG-5 column [$5\ \mu\text{m}$, $250 \times 9.4\ \text{mm}$] was employed for the purifications. All solvents used for CC and HPLC were of analytical grade (Shanghai Chemical Reagents Co., Ltd.) and chromatographic grade (Dikma Technologies Inc.), respectively.

3.2. Animal Materials

Specimens of *L. catalai*, identified by Prof. Xiu-Bao Li from Hainan University, were collected by scuba along the coast off Yalong Bay, Hainan Province, China, in 2006, at a depth of –15 meters. A voucher specimen (YAL-65) is deposited and available for inspection at the Bohai Rim Advanced Research Institute for Drug Discovery.

3.3. Extraction and Isolation

The frozen animals (260.5 g, dry weight after extraction) were cut into pieces and extracted exhaustively with acetone at room temperature ($2.0\ \text{L} \times 4$). The organic extract was evaporated to give a brown residue, which was then partitioned between Et_2O and H_2O . The Et_2O solution was evaporated to give a dark brown residue (12.0 g). The obtained residue was subjected to gradient silica gel (200–300 mesh) column chromatography (CC) [Et_2O /petroleum ether (PE) $0 \rightarrow 100\%$] yielded nine fractions (Fr. 1–9). Fr. 2 was divided into three sub-fractions (Fr. 2A–2C) by Sephadex LH-20 CC (PE/ CH_2Cl_2 /MeOH, 2:1:1). Following two-stage purification including Sephadex LH-20 CC (CH_2Cl_2 ,

100%) and silica gel CC (300–400 mesh, PE/Et₂O 100:1→10:1), the subfraction Fr. 2C13 was purified by semi-preparative HPLC (MeCN, 100%, 3.0 mL/min) and analytical HPLC (MeOH/H₂O, 80:20, 1.0 mL/min) to yield compounds **1** (2.0 mg, *t_R* = 16.4 min), **2** (0.3 mg, *t_R* = 18.4 min), and **4** (1.0 mg, *t_R* = 15.3 min), respectively. Fr. 6 was split by Sephadex LH-20 CC (PE/CH₂Cl₂/MeOH, 2:1:1) to give two subfractions (Fr. 6A and Fr. 6B). Next, Fr. 6B was purified by Sephadex LH-20 CC (CH₂Cl₂, 100%), yielding sub-fraction Fr. 6BA. Final purification of Fra. 6BA was achieved by Semi-preparative HPLC (MeOH/H₂O, 80:20, 2.8 mL/min) to afford compounds **7** (0.5 mg, *t_R* = 24.5 min), **6** (1.0 mg, *t_R* = 22.0 min) and the mixture of compounds **3** and **5**. The mixture was further purified by analytical HPLC (MeCN/H₂O, 60:40, 1.0 mL/min) to yield pure **3** (1.1 mg, *t_R* = 13.0 min) and **5** (1.0 mg, *t_R* = 14.6 min), respectively. Fr. 9 was subjected to a column of Sephadex LH-20 eluted with CH₂Cl₂/MeOH, 1:1, to yield two subfractions (Fr. 9A and 9B). Fr. 9A was first split by Sephadex LH-20 column chromatography (PE/CH₂Cl₂/MeOH, 2:1:1) to give five subfractions (Fr. 9AA–Fr. 9AE). Fr. 9AE was purified by RP-HPLC (MeCN/H₂O, 60:40, 3.0 mL/min), yielding a subfraction (Fr. 9AEC, *t_R* = 8.0 min). Since there are two points observed on the thin layer chromatography (TLC), Fr. 9AEC was purified by silica gel CC (300–400 mesh, CH₂Cl₂/MeOH, 96:4) to give compounds **12** (1.0 mg) and **14** (0.5 mg). Fr. 9AD was purified with silica gel CC (300–400 mesh, Et₂O/PE, 1:1), followed by semi-preparative HPLC (MeCN/H₂O, 60:40, 3.0 mL/min) to afford **13** (5.4mg, *t_R* = 2.1 min), **11** (3.2mg, *t_R* = 8.8 min) and fraction 9ADFG (*t_R* = 13.7min). In a similar manner, Fr. 9ADFG was purified by silica gel CC (300–400 mesh, CH₂Cl₂/MeOH, 98:2) to give compound **10** (2.6 mg). Moreover, compound **9** (2.7 mg, *t_R* = 7.3 min) was obtained from the Fr. 9B through Sephadex LH-20 CC (PE/CH₂Cl₂/MeOH, 2:1:1) followed by RP-HPLC (MeCN/H₂O, 60:40, 3.0 mL/min), while compound **15** (2.7 mg, *t_R* = 7.3 min) was obtained from the Fr. 9B through Sephadex LH-20 CC (PE/CH₂Cl₂/MeOH, 2:1:1), silica gel CC (200–300 mesh, Et₂O/PE 50%→100%), and followed by RP-HPLC (MeCN/H₂O, 60:40, 3.0 mL/min).

3.3.1. Lobocaline A (1)

Colorless crystal, m.p. 68.9–71.6 °C; [α]_D²⁰ +97.3 (c 0.20, CHCl₃); IR (KBr): ν_{\max} 3446, 2956, 2924, 2854, 1737, 1458, 1369, 1238, 1026 cm⁻¹; For ¹H and ¹³C NMR spectroscopic data, see Tables 1 and 2; HRESIMS m/z 347.2580 [M + H]⁺ (calcd. for C₂₂H₃₅O₃, 347.2581).

3.3.2. Lobocaline B (2)

Colorless oil, [α]_D²⁰ +3.9 (c 0.03, MeOH); IR (KBr): ν_{\max} 3444, 2956, 2917, 2849, 1731, 1030 cm⁻¹; For ¹H and ¹³C NMR spectroscopic data, see Tables 1 and 2; HRESIMS m/z 347.2581 [M + H]⁺ (calcd. for C₂₂H₃₅O₃, 347.2581).

3.3.3. Lobocaline C (3)

Colorless oil, [α]_D²⁰ +139.5 (c 0.10, MeOH); IR (KBr): ν_{\max} 3438, 2959, 2926, 1457, 1382, 1087, 1022 cm⁻¹; For ¹H and ¹³C NMR spectroscopic data, see Tables 1 and 2; HRESIMS m/z 327.2295 [M + Na]⁺ (calcd. for C₂₀H₃₂O₂Na, 327.2295).

3.3.4. Lobocaline D (4)

Colorless oil, [α]_D²⁰ +162.7 (c 0.10, CHCl₃); IR (KBr): ν_{\max} 3438, 2959, 2926, 1457, 1382, 1087, 1022 cm⁻¹; For ¹H and ¹³C NMR spectroscopic data, see Tables 1 and 2; HRESIMS m/z 327.2293 [M + Na]⁺ (calcd. for C₂₀H₃₂O₂Na, 327.2295).

3.3.5. Lobocaline E (5)

Colorless oil, [α]_D²⁰ +17.2 (c 0.10, CHCl₃); IR (KBr): ν_{\max} 3359, 2922, 2851, 1736, 1238, 1141, 1031 cm⁻¹; For ¹H and ¹³C NMR spectroscopic data, see Tables 1 and 2; HRESIMS m/z 369.2397 [M + Na]⁺ (calcd. for C₂₂H₃₄O₃Na, 369.2400).

3.3.6. Lobocaline F (9)

White amorphous powder, $[\alpha]_D^{20}$ +9.8 (c 0.27, MeOH); IR (KBr): ν_{\max} 3436, 2929, 2871, 1375, 1089, 1050 cm^{-1} ; For ^1H and ^{13}C NMR spectroscopic data, see Table 3; HRESIMS m/z 517.3504 $[\text{M} + \text{Na}]^+$ (calcd. for $\text{C}_{29}\text{H}_{50}\text{O}_6\text{Na}$, 517.35).

3.3.7. Lobocaline G (10)

White amorphous powder, $[\alpha]_D^{20}$ -8.3 (c 0.26, MeOH); IR (KBr): ν_{\max} 3444, 2930, 1730, 1369, 1260, 1050, 800 cm^{-1} ; For ^1H and ^{13}C NMR spectroscopic data, see Table 3; HRESIMS m/z 543.3655 $[\text{M} + \text{Na}]^+$ (calcd. for $\text{C}_{31}\text{H}_{52}\text{O}_6\text{Na}$, 543.3656).

3.3.8. Lobocaline H (11)

White amorphous powder, $[\alpha]_D^{20}$ -16.7 (c 0.32, MeOH); IR (KBr): ν_{\max} 3444, 2931, 2864, 1374, 1030 cm^{-1} ; For ^1H and ^{13}C NMR spectroscopic data, see Table 4; HRESIMS m/z 559.3609 $[\text{M} + \text{Na}]^+$ (calcd. for $\text{C}_{31}\text{H}_{52}\text{O}_7\text{Na}$, 559.3605).

3.3.9. Lobocaline I (12)

White amorphous powder; $[\alpha]_D^{20}$ -43.3 (c 0.10, MeOH); IR (KBr): ν_{\max} 3443, 2928, 2851, 1712, 1368, 1036 cm^{-1} ; For ^1H and ^{13}C NMR spectroscopic data, see Table 4; HRESIMS m/z 543.3653 $[\text{M} + \text{Na}]^+$ (calcd. for $\text{C}_{31}\text{H}_{52}\text{O}_6\text{Na}$, 543.3656).

3.4. Calculation Section

Conformational search was performed by using the torsional sampling (MCMM) approach and OPLS_2005 force field within an energy window of 21 kJ/mol. Conformers above 1% Boltzmann populations were re-optimized at the B3LYP/6-311G(d,p) level with the IEFPCM solvent model for chloroform. Frequency analysis was also carried out to confirm that the re-optimized geometries were at the energy minima. Subsequently, NMR calculations were performed at the PCM/mPW1PW91/6-31G(d) level, as recommended for DP4+. NMR shielding constants were calculated by using the GIAO method. Finally, shielding constants were averaged over the Boltzmann distribution obtained for each stereoisomer and correlated with the experimental data. ECD spectra were obtained by TDDFT calculations with the B3LYP/6-311G(d,p) level with the IEFPCM solvent model for CH_3CN . At last, the Boltzmann-averaged ECD spectra of the compounds were obtained with SpecDis 1.62.

3.5. Acetylation of Compound 6

Compound **6** (0.5 mg) was dissolved in dry pyridine (2.0 mL) and mixed with 50 mL of Ac_2O . The mixtures were stirred at room temperature overnight, and the reaction was detected on the TLC by heating after spraying with vanillin H_2SO_4 reagent. The crude acetylated product, after evaporating the solvent in vacuo, was purified by silica gel CC (petroleum ether/ether, 9:1) to afford a colorless crystal compound **1a** (0.5 mg, 87% yield), which was identical to the natural sample of **1** in all respect (Figure S1.10).

3.6. X-ray Crystallographic Analysis for Compounds 1 and 15a

Lobocaline A (**1**): colorless crystals, m.p. 68.9–71.6 $^{\circ}\text{C}$; monoclinic, $2(\text{C}_{22}\text{H}_{34}\text{O}_3)$, $M_r = 692.98$, crystal size: $0.11 \times 0.05 \times 0.04 \text{ mm}^3$, space group $P2_1$, $a = 10.6135(3) \text{ \AA}$, $b = 16.2226(5) \text{ \AA}$, $c = 11.8888(4) \text{ \AA}$, $V = 2044.73(11) \text{ \AA}^3$, $Z = 2$, $\rho_{\text{calc}} = 1.126 \text{ g/cm}^3$, $F(000) = 760.0$. Independent reflections: 7619 with $R_{\text{int}} = 0.0385$, $R_{\text{sigma}} = 0.0475$. Final $R_1 = 0.0479$, $wR_2 = 0.1174$ reflections with $I \geq 2\sigma(I)$, $R_1 = 0.0523$ ($wR_2 = 0.1215$) for all unique data, Flack parameter: 0.00(10). The crystals of **1** were recrystallized from MeOH at room temperature. X-ray crystallographic analysis was carried out on a Bruker D8 Venture

diffractometer with Cu K α radiation ($\lambda = 1.54178 \text{ \AA}$) at 100 K. The collected data integration and reduction were processed with SAINT V8.37A software, and multiscan absorption corrections were performed using the SADABS program. The structure was solved with the SHELXT structure solution program using intrinsic phasing and refined with the SHELXL refinement package using least squares minimization. Crystallographic data for **1** were deposited at the Cambridge Crystallographic Data Centre (Deposition nos. CCDC 2290865). Copies of these data can be obtained free of charge via www.ccdc.cam.ac.uk or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB21EZ, UK. [Fax: (+44) 1223-336-033. E-mail: deposit@ccdc.cam.ac.uk.]

Lobophytol B (**15a**): colorless crystals, m.p. 119.1–177.0 °C; monoclinic, C₂₀H₃₆O₄, Mr = 340.49, crystal size 0.15 × 0.08 × 0.05 mm³, space group I4, a = 14.6887(3) Å, b = 14.6887(3) Å, c = 37.2232(11) Å, V = 8031.2(4) Å³, Z = 16, $\rho_{\text{calc}} = 1.126 \text{ g/cm}^3$, F(000) = 3008.0, 57940 collected reflections, 8240 independent reflections ($R_{\text{int}} = 0.0620$, $R_{\text{sigma}} = 0.0327$), final $R_1 = 0.0399$ ($wR_2 = 0.1022$) reflections with $I \geq 2\sigma(I)$, $R_1 = 0.0431$, $wR_2 = 0.1051$ for all unique data, Flack parameter: 0.12(7). The crystals of **15a** were crystallized from acetone at room temperature. The X-ray measurements were made on a Bruker D8 Venture X-ray diffractometer with Cu K α radiation ($\lambda = 1.54178 \text{ \AA}$) at 100 K. The collected data integration and reduction were processed with SAINT V8.37A software, and multiscan absorption corrections were performed using the SADABS program. The structure was solved with the SHELXT structure solution program using intrinsic phasing and refined with the SHELXL refinement package using least squares minimization. Crystallographic data for **15a** were deposited at the Cambridge Crystallographic Data Centre (Deposition nos. CCDC 2290866). Copies of these data can be obtained free of charge via www.ccdc.cam.ac.uk or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB21EZ, UK. [Fax: (+44) 1223-336-033. E-mail: deposit@ccdc.cam.ac.uk.]

3.7. Antibacterial Activity Bioassays

The strains *Streptococcus parauberis* KSP28, *Streptococcus parauberis* SPOF3K, *Phyobacterium damsela* FP2244, *Aeromonas salmonicida* AS42, *Photobacterium halotolerans* LMG 22194T, *Enterococcus faecium* 5270 MDR8 and *Lactococcus garvieae* FP MP5245 were provided by National Fisheries Research & Development Institute, Korea. The vancomycin-resistant *Enterococcus faecium* bacteria G1, G4, G7, G8 and G13 were provided by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The strain *Streptococcus agalactiae* WR10 and *Edwardsiella piscicida* TH1 were provided by Chinese Academy of Tropical Agricultural Sciences. The MIC values for all antimicrobial agents were measured by 96-well micro-dilution method. Mueller–Hinton II broth (cation-adjusted, BD 212322) was used for MIC value determination. Generally, compounds were dissolved with DMSO to 20 mM as stock solutions. All samples were diluted with culture broth to 500 μM as the initial concentration. Further 1:2 serial dilutions were performed by addition of culture broth to reach concentrations ranging from 500 μM to 0.24 μM . 100 μL of each dilution was distributed in 96-well plates, as well as sterile controls, growth controls (containing culture broth plus DMSO, without compounds), and positive controls (containing culture broth plus control antibiotics such as tetracycline). Each test and growth control wells were inoculated with 5 μL of an exponential-phase bacterial suspension (about 10^5 CFU/well). The 96-well plates were incubated at 37 °C for 24 h. MIC values of these compounds were defined as the lowest concentration to inhibit the bacterial growth completely. All MIC values were interpreted according to recommendations of the Clinical and Laboratory Standards Institute (CLSI).

3.8. Antihemolytic Activity Bioassays

Blood was collected from the eye sockets of SD rats and stood for 30 to 60 minutes. After centrifugation (800 rpm, 5 min), the red blood cells were cleaned twice with 0.9% normal saline and then added to create a 4% red blood cells suspension. *S. aureus* suspension was incubated with compounds (100 μM) in a centrifuge tube for 12 h at 37 °C. After centrifugation (6000 rpm, 15 min), 500 μL of the supernatant was taken from each tube, filtered by 0.2 μm filter membrane, and incubated with 500 μL of freshly red blood cells suspension at 37 °C for 2 h. The incubation of *S.*

aureus and red blood cells suspension was used as the positive control, and the incubation of LB liquid medium and red blood cells suspension served as the negative control. After centrifugation (800 rpm, 5 min), the absorbance of supernatants at 540 nm was examined. The percentage of hemolysis value was calculated by comparing it with the positive control (100% hemolysis).

3.9. Pyocyanin Quantitation Assay

P. aeruginosa strain was mixed with the compounds (100 μ M) at 37°C, 140 rpm/min for 24 hours, and the supernatant was mixed with 1 mL chloroform. Then the lower chloroform phase was mixed with 200 μ L of 0.2 N HCl, after shaking and centrifugal (4500 rpm, 10 min), the color layer was removed and measured at 520 nm. Concentrations, expressed as micrograms of pyocyanin produced per milliliter of culture supernatant, were determined by multiplying the optical density at 520 nm (OD₅₂₀) by 17.072.

4. Conclusion

In summary, five new cembrane-type diterpenes lobocalines A–E (1–5) and four new steroids lobocalines F–I (9–12), along six known analogues (6–8 and 13–15) were isolated and characterized from the soft coral *L. catalai* collected off Yalong Bay of the South China Sea. Structurally, all the isolated new cembrane-type diterpenes have hydroxyl or acetoxy groups substituted at C-5, C-6, or C-7. All the steroids possessed the hydroxyl groups at C-3, C-5, and C-6, and the stereotypes of hydroxyl groups (3 β , 5 β , 6 α or 3 β , 5 α , 6 β) are significantly different in 9–14. It is worth to note that the structure of known compound 15 has been revised by the X-ray diffraction analysis in this study.

In the bioassays, compounds 2 and 7–14 showed antibacterial activities against the fish pathogenic bacteria *S. parauberis* KSP28 with MIC values ranging from 12.3 to 53.6 μ g/mL. Compound 13 displayed potent inhibitory activity against *P. damsela* FP2244 with MIC value of 6.2 μ g/mL. Compounds 10 (3 β , 5 β , 6 α) and 12 (3 β , 5 α , 6 β) have different configurations, and the antibacterial activity of compound 10 was stronger than that of 12, suggested the importance of stereochemistry for bioactivity. Further study should be conducted to explore the effect of different cholestane-3,5,6-triols configurations (3 β , 5 β , 6 α or 3 β , 5 α , 6 β) on antibacterial activities. These new findings implied these isolated compounds could be developed as new chemotypes of lead agents against fish pathogens, which may have the beneficial effect on fish health in the future. In addition, the findings reveal that compounds 2, 7, and 14 have remarkable inhibition effects on the virulence of *S. aureus*, supporting their potential as the natural antimicrobial agent to combat *S. aureus*.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org.

Funding: This work was financially supported by the National Natural Science Foundation of China (NSFC) (No. 81991521, 41876194), Shandong Laboratory Program (No. SYS202205).

Institutional Review Board Statement: Not applicable.

Data Availability Statement: Data are contained within the article or Supplementary Materials.

Acknowledgments: The authors thank Prof. X.-B. Li from Hainan University for the taxonomic identification of the soft coral material. The authors thank Shanghai Supercomputer Center for the computing services.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Chi, L. P.; Liu, D.; Li, X. M.; Wan, Y. P.; Wang, B. G.; Li, X. Aspertides A-E: Antimicrobial pentadepsipeptides with a unique p-Methoxycinnamoyl amide group from the marine isolates *Aspergillus tamarii* MA-21 and *Aspergillus insuetus* SD-512. *J. Agric. Food Chem.* **2023**, *71*, 13316–13324.
2. Guo, S. Y.; Zhang, Z. Y.; Guo, L. Antibacterial molecules from marine microorganisms against aquatic pathogens: A Concise Review. *Mar. Drugs* **2022**, *20*.
3. Li, S. W.; Yu, D. D.; Su, M. Z.; Yao, L. G.; Wang, H.; Liu, X. T.; Guo, Y. W. Ocellatuspyrones A-G, new antibacterial polypropionates from the Chinese mollusk ocellatus. *Mar. Life Sci. Technol.* **2023**, *5*, 373–386.

4. Gao, K.; Su, B.; Dai, J.; Li, P.; Wang, R.; Yang, X. Anti-biofilm and anti-hemolysis activities of 10-Hydroxy-2-decenoic acid against *Staphylococcus aureus*. *Molecules* **2022**, *27*.
5. McDermott, C.; Chess-Williams, R.; Grant, G. D.; Perkins, A. V.; McFarland, A. J.; Davey, A. K.; Anoopkumar-Dukie, S. Effects of *Pseudomonas aeruginosa* virulence factor pyocyanin on human urothelial cell function and viability. *J. Urol.* **2012**, *187*, 1087–1093.
6. Carroll, A. R.; Copp, B. R.; Davis, R. A.; Keyzers, R. A.; Prinsep, M. R. Marine natural products. *Nat. Prod. Rep.* **2020**, *37*, 175–223.
7. Elkhoully, H. B.; Attia, E. Z.; Khedr, A. I. M.; Samy, M. N.; Fouad, M. A. Recent updates on *Sinularia* soft coral. *Mini-Rev in Med Chem.* **2022**, *22*, 1152–1196.
8. He, X.; Yan, S.; Zeng, L.; Su, J. Studies on the secondary metabolite of the soft coral *Lobophytum* sp.(II). *Acta Scientiarum Natu raliu m Universitatis Sunyatseni* **2005**, *44*, 113–115.
9. Sarma, N. S.; Krishna, M. S.; Pasha, S. G.; Rao, T. S. P. Venkateswarlu, Y.; Parameswaran, P. S. Marine metabolites: The Sterols of Soft Coral. *Chem. Rev.* **2009**, *109*, 2803–2828.
10. Yin, S. W.; Shi, Y. P.; Li, X. M.; Wang, B. G. A novel hydroperoxyl substituted cembranolide diterpene from marine soft coral *Lobophytum crassum*. *Chin. Chem. Lett.* **2005**, *16*, 1489–1491.
11. Li, S. W.; Cuadrado, C.; Yao, L. G.; Daranas, A. H.; Guo, Y. W. Quantum mechanical-NMR-Aided configuration and confor mation of two unreported macrocycles isolated from the soft coral *Lobophytum* sp.: Energy Calculations versus Coupling Constants. *Org Lett* **2020**, *22*, 4093–4096.
12. Liu, J.; Gu, Y. C.; Su, M. Z.; Guo, Y. W. Chemistry and bioactivity of secondary metabolites from South China Sea marine fauna and flora: recent research advances and perspective. *Acta Pharmacol. Sin.* **2022**, *43*, 3062–3079.
13. Anjaneyulu, A. S. R.; Rao, N. S. K.; Sagar, K. S. Two new cembranoids from the soft coral *Lobophytum catalai* Tixier-Durivault of the Andaman and Nicobar Islands. *Indian J Chem B.* **1998**, *37*, 267–274.
14. Anjaneyulu, A. S. R.; Rao, N. S. K.; Venugopal, M. A novel furanosesquiterpenoid from the soft coral *Lobophytum catalai* Tixier-Durivault of the Andaman and Nicobar Islands. *Indian J Chem B.* **1996**, *35*, 1001–1003.
15. Zhang, J.; Ma, H.; Jin, S.; Liu, X.; Li, L.; Liu, Z.; Li, G.; Li, P. Seven new lobane diterpenoids from the soft coral *Lobophytum catalai*. *Mar. Drugs* **2023**, *21*.
16. Wan, Y.; Zeng, Z.; Zeng, L. Study on the steroids from the soft coral *Lobophytum catalai*. *Zhongshan Daxue Xuebao, Ziran Kexueban* **1996**, *35* (Suppl. 2), 171–172.
17. Shen, S.-M.; Appendino, G.; Guo, Y.-W. Pitfalls in the structural elucidation of small molecules. A critical analysis of a decade of structural misassignments of marine natural products. *Nat. Prod. Rep.* **2022**, *39*, 1803–1832.
18. Yu, J.-D.; Su, M.-Z.; Gu, Y.-C.; Yu, D.-D.; Yao, L.-G.; Shen, S.-M.; Guo, Y.-W.; Wang, H. Two new cembranoids from the Chinese soft coral *Sarcophyton boettgeri*. *Chem. & Biodivers.* **2023**.
19. Duh, C. Y.; Hou, R. S. Cytotoxic cembranoids from the soft corals *Sinularia gibberosa* and *Sarcophyton trocheliophorum*. *J. Nat. Prod.* **1996**, *59*, 595–598.
20. Liang, L.-F.; Chen, W.-T.; Mollo, E.; Yao, L.-G.; Wang, H.-Y.; Xiao, W.; Guo, Y.-W. Sarcophytols G - L, novel minor metabolic components from South China Sea soft coral *Sarcophyton trocheliophorum* MARENZELLER. *Chem. & Biodivers.* **2017**, *14*.
21. Yamada, Y.; Suzuki, S.; Iguchi, K.; Kikuchi, H.; Tsukitani, Y.; Horiai, H.; Nakanishi, H. Studies on marine natural-products. 2. New polyhydroxylated sterols from the soft coral *Lobophytum-pauciflorum*(ehrenberg). *Chem. Pharm. Bull.* **1980**, *28*, 473–478.
22. Zidan, S. A. H.; Abdelhamid, R. A.; Al-Hammady, M.; Fouad, M. A.; Matsunami, K.; Orabi, M. A. A. Cytotoxic polyhydroxy sterols from the Egyptian Red Sea soft coral *Sarcophyton acutum*. *Fitoterapia* **2020**, *147*, 104765.
23. Zhang, Q.; Li, X. W.; Yao, L. G.; Wu, B.; Guo, Y. W. Three new capnosane-type diterpenoids from the South China Sea soft coral *Lobophytum* sp. *Fitoterapia* **2019**, *133*, 70–74.
24. Subrahmanyam, C.; Rao, C. V.; Anjaneyulu, V.; Satyanarayana, P.; Rao, P. V. S.; Ward, R. S.; Pelter, A. New diterpenes from a new species of *Lobophytum* soft coral of the South Andaman Coast. *Tetrahedron* **1992**, *48*, 3111–3120.
25. Huang, C. Y.; Tseng, W. R.; Ahmed, A. F.; Chiang, P. L.; Tai, C. J.; Hwang, T. L.; Dai, C. F.; Sheu, J. H. Anti-inflammatory polyoxygenated sterols from the soft coral *Lobophytum michaelae*. *Mar. Drugs* **2018**, *16*.
26. Li, R.; Shao, C.-L.; Qi, X.; Li, X.-B.; Li, J.; Sun, L.-L.; Wang, C.-Y. Polyoxygenated sterols from the South China Sea soft coral *Sinularia* sp. *Mar. Drugs* **2012**, *10*, 1422–1432.
27. Zhao, K.; Wang, Y.; Han, L. 4,5-Epoxycholestane-3,6-diols: templates for generating the full set of eight cholestane-3,5,6-triol stereoisomers in multigram scales, but not for a cholestane-3,4,6-triol. *Steroids* **2007**, *72*, 95–104.
28. Lu, Y.; Lin, Y.-C.; Wen, Z.-H.; Su, J.-H.; Sung, P.-J.; Hsu, C.-H.; Kuo, Y.-H.; Chiang, M. Y.; Dai, C.-F.; Sheu, J.-H. Steroid and cembranoids from the Dongsha atoll soft coral *Lobophytum sarcophytoides*. *Tetrahedron* **2010**, *66*, 7129–7135.

29. Bawakid, N. O.; Alarif, W. M.; Abdel-Lateff, A. Rare norisodinosterol derivatives from *Xenia umbellata*: Isolation and anti-proliferative activity. *Open Chem.* **2021**, *19*, 400–407.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.